|
1
|
Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N
and Zhao Y: Recent progress in treatment of hepatocellular
carcinoma. Am J Cancer Res. 10:2993–3036. 2020.PubMed/NCBI
|
|
2
|
Zhu ZX, Huang JW, Liao MH and Zeng Y:
Treatment strategy for hepatocellular carcinoma in China:
Radiofrequency ablation versus liver resection. Jpn J Clin Oncol.
46:1075–1080. 2016.PubMed/NCBI
|
|
3
|
Perera S, Kelly D and O'Kane GM:
Non-immunotherapy options for the first-line management of
hepatocellular carcinoma: Exploring the evolving role of sorafenib
and lenvatinib in advanced disease. Curr Oncol. 27 (Suppl
3):S165–S172. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Yao Z, Chen Y, Qian L, Jiang S,
Zhou J, Shao J, Chen A, Zhang F and Zheng S: Lipophagy and liver
disease: New perspectives to better understanding and therapy.
Biomed Pharmacother. 97:339–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maan M, Peters JM, Dutta M and Patterson
AD: Lipid metabolism and lipophagy in cancer. Biochem Biophys Res
Commun. 504:582–589. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Madrigal-Matute J and Cuervo AM:
Regulation of liver metabolism by autophagy. Gastroenterology.
150:328–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beloribi-Djefaflia S, Vasseur S and
Guillaumond F: Lipid metabolic reprogramming in cancer cells.
Oncogenesis. 5:e1892016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong H and Czaja MJ: Regulation of lipid
droplets by autophagy. Trends Endocrinol Metab. 22:234–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mondal S, Roy D, Sarkar Bhattacharya S,
Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, et
al: Therapeutic targeting of PFKFB3 with a novel glycolytic
inhibitor PFK158 promotes lipophagy and chemosensitivity in
gynecologic cancers. Int J Cancer. 144:178–189. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li X, Zhou Y, Yang L, Ma Y, Peng X, Yang
S, Li H and Liu J: LncRNA NEAT1 promotes autophagy via regulating
miR-204/ATG3 and enhanced cell resistance to sorafenib in
hepatocellular carcinoma. J Cell Physiol. 235:3402–3413. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang S, Wang M, Yang L, Li Y, Ma Y, Peng
X, Li X, Li B, Jin H and Li H: MicroRNA-375 Targets ATG14 to
inhibit autophagy and sensitize hepatocellular carcinoma cells to
sorafenib. Onco Targets Ther. 13:3557–3570. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lapierre LR, Kumsta C, Sandri M, Ballabio
A and Hansen M: Transcriptional and epigenetic regulation of
autophagy in aging. Autophagy. 11:867–880. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maiese K: Targeting the core of
neurodegeneration: FoxO, mTOR, and SIRT1. Neural Regen Res.
16:448–455. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sathyanarayan A, Mashek MT and Mashek DG:
ATGL promotes autophagy/lipophagy via SIRT1 to control hepatic
lipid droplet catabolism. Cell Rep. 19:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masters JR, Thomson JA, Daly-Burns B, Reid
YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, et
al: Short tandem repeat profiling provides an international
reference standard for human cell lines. Proc Natl Acad Sci USA.
98:8012–8017. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li HR, Shagisultanova EI, Yamashita K,
Piao Z, Perucho M and Malkhosyan SR: Hypersensitivity of tumor cell
lines with microsatellite instability to DNA double strand break
producing chemotherapeutic agent bleomycin. Cancer Res.
64:4760–4767. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohata Y, Shimada S, Akiyama Y, Mogushi K,
Nakao K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, et
al: Acquired resistance with epigenetic alterations under Long-Term
antiangiogenic therapy for hepatocellular carcinoma. Mol Cancer
Ther. 16:1155–1165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Regan-Fendt K, Li D, Reyes R, Yu L, Wani
NA, Hu P, Jacob ST, Ghoshal K, Payne PRO and Motiwala T:
Transcriptomics-Based drug repurposing approach identifies novel
drugs against Sorafenib-Resistant hepatocellular carcinoma. Cancers
(Basel). 12:27302020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pu Z, Zhu Y, Wang X, Zhong Y, Peng F and
Zhang Y: Identification of prognostic biomarkers and correlation
with immune infiltrates in hepatocellular carcinoma based on a
competing endogenous RNA network. Front Genet. 12:5916232021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang Q, Li T, Chen P, Wu Y, Wang T, Mo L,
Ou J and Nandakumar KS: Comparative analysis on abnormal methylome
of differentially expressed genes and disease pathways in the
immune cells of RA and SLE. Front Immunol. 12:6680072021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi Z, Kong X, Li C, Liu H, Aliagan AI,
Liu L, Shi Y, Shi X, Ma B, Jin R, et al: Bioinformatic analysis of
differentially expressed genes as prognostic markers in
pheochromocytoma and paraganglioma tumors. Genes Genet Syst.
96:55–69. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu M, Fan X, Liao W, Li Y, Ma L, Yuan M,
Gu R, Wei Z, Wang C and Zhang H: Identification of significant
genes as prognostic markers and potential tumor suppressors in lung
adenocarcinoma via bioinformatical analysis. BMC Cancer.
21:6162021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kozomara A, Birgaoanu M and
Griffiths-Jones S: MiRBase: From microRNA sequences to function.
Nucleic Acids Res. 47:D155–D162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinez-Lopez N and Singh R: Autophagy
and lipid droplets in the liver. Annu Rev Nutr. 35:215–237. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thai SF, Jones CP, Robinette BL, Ren H,
Vallanat B, Fisher AA and Kitchin KT: Effects of silver
nanoparticles and silver nitrate on mRNA and microRNA expression in
human hepatocellular carcinoma cells (HepG2). J Nanosci
Nanotechnol. 21:5414–5428. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noto A, De Vitis C, Pisanu ME, Roscilli G,
Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati
O, Trisciuoglio D, et al: Stearoyl-CoA-desaturase 1 regulates lung
cancer stemness via stabilization and nuclear localization of
YAP/TAZ. Oncogene. 36:4573–4584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kikuchi K and Tsukamoto H: Stearoyl-CoA
desaturase and tumorigenesis. Chem Biol Interact. 316:1089172020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tesfay L, Paul BT, Konstorum A, Deng Z,
Cox AO, Lee J, Furdui CM, Hegde P, Torti FM and Torti SV:
Stearoyl-CoA Desaturase 1 protects ovarian cancer cells from
ferroptotic cell death. Cancer Res. 79:5355–5366. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pisanu ME, Noto A, De Vitis C, Morrone S,
Scognamiglio G, Botti G, Venuta F, Diso D, Jakopin Z, Padula F, et
al: Blockade of Stearoyl-CoA-desaturase 1 activity reverts
resistance to cisplatin in lung cancer stem cells. Cancer Lett.
406:93–104. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi M, Li J, Chen S, Cai J, Ban Y, Peng Q,
Zhou Y, Zeng Z, Peng S, Li X, et al: Emerging role of lipid
metabolism alterations in cancer stem cells. J Exp Clin Cancer Res.
37:1182018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L,
Qiang L, Gao S and Gao Y: Co-delivery of autophagy inhibitor ATG7
siRNA and docetaxel for breast cancer treatment. J Control Release.
266:272–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiong H, Ni Z, He J, Jiang S, Li X, He J,
Gong W, Zheng L, Chen S, Li B, et al: LncRNA HULC triggers
autophagy via stabilizing Sirt1 and attenuates the chemosensitivity
of HCC cells. Oncogene. 36:3528–3540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu H, Shang J, Zhan W, Liu J, Ning H and
Chen N: MiR4255p promotes cell proliferation, migration and
invasion by directly targeting FOXD3 in hepatocellular carcinoma
cells. Mol Med Rep. 20:1883–1892. 2019.PubMed/NCBI
|
|
37
|
Rao D, Guan S, Huang J, Chang Q and Duan
S: MiR-425-5p acts as a molecular marker and promoted
proliferation, migration by targeting RNF11 in hepatocellular
carcinoma. Biomed Res Int. 2020:65309732020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vaira V, Roncalli M, Carnaghi C, Faversani
A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di
Tommaso L, et al: MicroRNA-425-3p predicts response to sorafenib
therapy in patients with hepatocellular carcinoma. Liver Int.
35:1077–1086. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Portmann S, Fahrner R, Lechleiter A, Keogh
A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D
and Stroka D: Antitumor effect of SIRT1 inhibition in human HCC
tumor models in vitro and in vivo. Mol Cancer Ther. 12:499–508.
2013. View Article : Google Scholar : PubMed/NCBI
|
